REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: Hard Brexit, Putin, Hammond

Sun, 15th Jan 2017 16:35

(ShareCast News) - Theresa May will announce that Britain is seeking a clean and hard Brexit in a speech this week that will promise to create a "strong new partnership" with the European Union. The prime minister will finally lay her cards on the table, making clear that the UK is set to pull out of the single market and the European customs union in order to regain control of immigration and end the jurisdiction of the European Court of Justice. - The Sunday TimesDonald Trump is planning to hold a summit with Vladimir Putin within weeks of becoming president - emulating Ronald Reagan's Cold War deal-making in Reykjavik with Mikhail Gorbachev. Trump and his team have told British officials that their first foreign trip will be a meeting with the Russian leader, with the Icelandic capital in pole position to host the superpower talks as it did three decades ago. In a bid to reset western relations with the Kremlin, Trump will begin work on a deal limiting nuclear weapons. - The Sunday TimesThe chancellor, Philip Hammond, has suggested Britain could transform its economic model into that of a corporate tax haven if the EU fails to provide it with an agreement on market access after Brexit. In an interview with the German newspaper Welt am Sonntag, Hammond said that if Britain were closed off from European markets after leaving the EU, it would consider abandoning a European-style social model with European-style taxation and regulation systems, and "become something different". - The GuardianThe US media giant 21st Century Fox and Sky have begun privately reassuring MPs about plans for their controversial £18bn merger, in hopes of heading off political opposition to full Murdoch control of Britain's dominant pay-TV operator. Lobbyists for the two companies are fielding inquiries from all sides of the Commons by insisting that the deal will not mean changes to Sky News. - The Sunday TelegraphTata Steel's offer to pay 'hundreds of millions' of pounds into its pension scheme in return for the release of the fund's claim over the firm's key Dutch plant is unlikely to clear the way for the company to hive off the scheme, experts warn. The Tata Group is looking at merging its European steel operations, including Tata Steel UK, with German steelmaker ThyssenKrupp. But Tata says it needs to separate the 130,000-member British Steel Pension Scheme from the business for the plan to go ahead. - The Mail on SundayA bidder for the Green Investment Bank (GIB) has launched a last-minute attempt to seize control of the state-owned eco-friendly lender. The government is weeks away from awarding Australian bank Macquarie the taxpayer-owned renewable energy lender in a deal worth £3.8bn. However, Jonathan Maxwell, chief executive of Sustainable Development Capital (SDC) has urged energy minister Nick Hurd to reject the Macquarie bid. - The Sunday TimesThe US may soon adopt a more European approach to drugs procurement, with a national body or insurance companies tasked with negotiating on pricing, amid mounting concern that president-elect Donald Trump is planning a major clampdown. US government-funded healthcare programmes, such as Medicare and Medicaid, are not allowed to negotiate on pricing, which means prices of certain drugs have soared in recent years. - The Sunday Telegraph
More News
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.